File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A phase II study of entecavir vs lamivudine in adults with chronic hepatitis B

TitleA phase II study of entecavir vs lamivudine in adults with chronic hepatitis B
Authors
Issue Date2001
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 36th Annual Meeting of the European Association for the Study of the Liver, Prague, Czech Republic, 18-22 April 2001. In Journal of Hepatology, 2001, v. 34 n. S1, p. 24 Abstract no. 1586 How to Cite?
AbstractBackground: Entecavir (ETV) is a guanosine nucleoside analogue which has demonstrated potent activity against hepatitis B virus (HBV) in vitro (EDsc=4nM), in animal models and in a previous 4-week dosing trial in adults with chronic hepatitis B. Methods: The safety and antiviral activity of 3 doses of ETV (0.01, 0.1 and 0.5 mg QD) given for 24 weeks compared to lamivudine (LVD) 100 mg QD were studied in a double-blind, randomized trial in 180 subjects (45/arm). HBeAg-positive and -negative subjects with HBV DNA levels 240 MEq/mL by the Quantiplex” bDNA assay who had not received r 12 weeks of prior anti-HBV therapy with nucleosides were eligible. The primary endpoint was mean log10 HBV DNA measured by the Roche Amplicoi” PCR assay at Week 22. Results: 177 subjects started study drug and 169 were evaluable for efficacy. The majority were male (74%). Asian (57%), HBeAg-positive (81%), with mean ALT of 109 ID/L and mean logta HBV DNA of 2.8 MEq/mL. 22% of subjects had received prior interferon therapy. All 3 doses of ETV were active, but the 0.01 mg dose was less effective than the 0.1 and 0.5 mg doses. ETV 0.1 and 0.5 mg doses were both superior to LVD with mean logto reductions in HBV DNA by PCR of 4.3, 4.7 and 3.4, respectively (p=O.OOOl) at Week 22. Only 6 subjects (4 ETV, 2 LVD) lost HBeAg. There was a suggestion of greater normalization of serum ALT for the 2 higher doses of ETV (83% and 66%) than for LVD (59%), but these differences were not statistically significant. ETV was generally well tolerated. Mild-to-moderate adverse events attributable to the nervous system were more frequent in the ETV 0.5 mg group than for LVD; however, only 1 ETV subject in the 0.1 mg group discontinued after 18 weeks of dosing due to lethargy andphotosensitivity. Conclusion: Entecavir at doses of 0.1 and 0.5 mg once daily has superior antiviral activity to lamivudine and is well tolerated.
Persistent Identifierhttp://hdl.handle.net/10722/101033
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_HK
dc.contributor.authorRosmawati, M-
dc.contributor.authorLao, J-
dc.contributor.authorVan Vlierberghe, H-
dc.contributor.authorAnderson, F-
dc.contributor.authorThomas, N-
dc.contributor.authorDe Hertogh, D-
dc.date.accessioned2010-09-25T19:33:17Z-
dc.date.available2010-09-25T19:33:17Z-
dc.date.issued2001en_HK
dc.identifier.citationThe 36th Annual Meeting of the European Association for the Study of the Liver, Prague, Czech Republic, 18-22 April 2001. In Journal of Hepatology, 2001, v. 34 n. S1, p. 24 Abstract no. 1586-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/101033-
dc.description.abstractBackground: Entecavir (ETV) is a guanosine nucleoside analogue which has demonstrated potent activity against hepatitis B virus (HBV) in vitro (EDsc=4nM), in animal models and in a previous 4-week dosing trial in adults with chronic hepatitis B. Methods: The safety and antiviral activity of 3 doses of ETV (0.01, 0.1 and 0.5 mg QD) given for 24 weeks compared to lamivudine (LVD) 100 mg QD were studied in a double-blind, randomized trial in 180 subjects (45/arm). HBeAg-positive and -negative subjects with HBV DNA levels 240 MEq/mL by the Quantiplex” bDNA assay who had not received r 12 weeks of prior anti-HBV therapy with nucleosides were eligible. The primary endpoint was mean log10 HBV DNA measured by the Roche Amplicoi” PCR assay at Week 22. Results: 177 subjects started study drug and 169 were evaluable for efficacy. The majority were male (74%). Asian (57%), HBeAg-positive (81%), with mean ALT of 109 ID/L and mean logta HBV DNA of 2.8 MEq/mL. 22% of subjects had received prior interferon therapy. All 3 doses of ETV were active, but the 0.01 mg dose was less effective than the 0.1 and 0.5 mg doses. ETV 0.1 and 0.5 mg doses were both superior to LVD with mean logto reductions in HBV DNA by PCR of 4.3, 4.7 and 3.4, respectively (p=O.OOOl) at Week 22. Only 6 subjects (4 ETV, 2 LVD) lost HBeAg. There was a suggestion of greater normalization of serum ALT for the 2 higher doses of ETV (83% and 66%) than for LVD (59%), but these differences were not statistically significant. ETV was generally well tolerated. Mild-to-moderate adverse events attributable to the nervous system were more frequent in the ETV 0.5 mg group than for LVD; however, only 1 ETV subject in the 0.1 mg group discontinued after 18 weeks of dosing due to lethargy andphotosensitivity. Conclusion: Entecavir at doses of 0.1 and 0.5 mg once daily has superior antiviral activity to lamivudine and is well tolerated.-
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatologyen_HK
dc.titleA phase II study of entecavir vs lamivudine in adults with chronic hepatitis Ben_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0168-8278(01)80947-8-
dc.identifier.hkuros62023en_HK
dc.identifier.hkuros62150-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats